MA54447A - Dérivés de 7-phénoxy-n-(3-azabicyclo[3.2.1]octan-8-yl)-6,7-dihydro-5h-pyrrolo[1,2-b][1,2,4]triazol-2-amine et composés apparentés en tant que modulateurs de gamma-sécrétase pour le traitement de la maladie d'alzheimer - Google Patents
Dérivés de 7-phénoxy-n-(3-azabicyclo[3.2.1]octan-8-yl)-6,7-dihydro-5h-pyrrolo[1,2-b][1,2,4]triazol-2-amine et composés apparentés en tant que modulateurs de gamma-sécrétase pour le traitement de la maladie d'alzheimerInfo
- Publication number
- MA54447A MA54447A MA054447A MA54447A MA54447A MA 54447 A MA54447 A MA 54447A MA 054447 A MA054447 A MA 054447A MA 54447 A MA54447 A MA 54447A MA 54447 A MA54447 A MA 54447A
- Authority
- MA
- Morocco
- Prior art keywords
- octan
- azabicyclo
- pyrrolo
- triazol
- alzheimer
- Prior art date
Links
- VHNYOQKVZQVBLC-RTCGXNAVSA-N (4r,7e,9as)-7-[[3-methoxy-4-(4-methylimidazol-1-yl)phenyl]methylidene]-4-(3,4,5-trifluorophenyl)-1,3,4,8,9,9a-hexahydropyrido[2,1-c][1,4]oxazin-6-one Chemical compound C1([C@@H]2COC[C@@H]3CC\C(C(N32)=O)=C/C=2C=C(C(=CC=2)N2C=C(C)N=C2)OC)=CC(F)=C(F)C(F)=C1 VHNYOQKVZQVBLC-RTCGXNAVSA-N 0.000 title 1
- 208000024827 Alzheimer disease Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 229940124648 γ-Secretase Modulator Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18212199 | 2018-12-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA54447A true MA54447A (fr) | 2022-03-23 |
Family
ID=64665266
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA054447A MA54447A (fr) | 2018-12-13 | 2019-12-11 | Dérivés de 7-phénoxy-n-(3-azabicyclo[3.2.1]octan-8-yl)-6,7-dihydro-5h-pyrrolo[1,2-b][1,2,4]triazol-2-amine et composés apparentés en tant que modulateurs de gamma-sécrétase pour le traitement de la maladie d'alzheimer |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20220056036A1 (fr) |
| EP (1) | EP3894411B1 (fr) |
| JP (1) | JP2022513466A (fr) |
| KR (1) | KR20210102900A (fr) |
| CN (2) | CN113179641B (fr) |
| AR (1) | AR116906A1 (fr) |
| AU (1) | AU2019395774A1 (fr) |
| BR (1) | BR112021009443A2 (fr) |
| CA (1) | CA3117870A1 (fr) |
| CL (1) | CL2021001547A1 (fr) |
| CO (1) | CO2021006837A2 (fr) |
| CR (1) | CR20210305A (fr) |
| IL (2) | IL310081A (fr) |
| MA (1) | MA54447A (fr) |
| MX (1) | MX2021006761A (fr) |
| PE (1) | PE20211776A1 (fr) |
| SG (1) | SG11202103340PA (fr) |
| TW (1) | TWI831892B (fr) |
| WO (1) | WO2020120521A1 (fr) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8703763B2 (en) * | 2011-03-02 | 2014-04-22 | Hoffmann-La Roche Inc. | Bridged piperidine derivatives |
| CN107922437B (zh) * | 2015-09-09 | 2021-12-10 | 豪夫迈·罗氏有限公司 | 桥连哌啶衍生物 |
| EP3386978B1 (fr) * | 2015-12-10 | 2021-01-27 | H. Hoffnabb-La Roche Ag | Dérivés de pipéridine pontés |
| CN109311878B (zh) * | 2016-06-27 | 2022-05-24 | 豪夫迈·罗氏有限公司 | 作为γ-分泌酶调节剂的三唑并吡啶类化合物 |
| WO2018083050A1 (fr) * | 2016-11-01 | 2018-05-11 | F. Hoffmann-La Roche Ag | Dérivés hétéroaryle bicycliques |
| AR110122A1 (es) * | 2016-11-08 | 2019-02-27 | Hoffmann La Roche | Fenoxitriazoles |
| KR20190098998A (ko) | 2016-12-16 | 2019-08-23 | 파이프라인 테라퓨틱스, 아이엔씨. | 달팽이관 시냅스질환의 치료 방법 |
-
2019
- 2019-12-11 CN CN201980076253.8A patent/CN113179641B/zh active Active
- 2019-12-11 AU AU2019395774A patent/AU2019395774A1/en active Pending
- 2019-12-11 JP JP2021533563A patent/JP2022513466A/ja active Pending
- 2019-12-11 US US17/413,413 patent/US20220056036A1/en active Pending
- 2019-12-11 MX MX2021006761A patent/MX2021006761A/es unknown
- 2019-12-11 EP EP19824250.5A patent/EP3894411B1/fr active Active
- 2019-12-11 CA CA3117870A patent/CA3117870A1/fr active Pending
- 2019-12-11 SG SG11202103340PA patent/SG11202103340PA/en unknown
- 2019-12-11 PE PE2021000726A patent/PE20211776A1/es unknown
- 2019-12-11 BR BR112021009443-1A patent/BR112021009443A2/pt unknown
- 2019-12-11 KR KR1020217017774A patent/KR20210102900A/ko unknown
- 2019-12-11 IL IL310081A patent/IL310081A/en unknown
- 2019-12-11 CR CR20210305A patent/CR20210305A/es unknown
- 2019-12-11 MA MA054447A patent/MA54447A/fr unknown
- 2019-12-11 WO PCT/EP2019/084538 patent/WO2020120521A1/fr unknown
- 2019-12-11 CN CN202311792520.6A patent/CN117946116A/zh active Pending
- 2019-12-12 AR ARP190103631A patent/AR116906A1/es unknown
- 2019-12-12 TW TW108145480A patent/TWI831892B/zh active
-
2021
- 2021-05-24 CO CONC2021/0006837A patent/CO2021006837A2/es unknown
- 2021-06-08 IL IL283823A patent/IL283823B2/en unknown
- 2021-06-11 CL CL2021001547A patent/CL2021001547A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PE20211776A1 (es) | 2021-09-08 |
| MX2021006761A (es) | 2021-07-15 |
| CN117946116A (zh) | 2024-04-30 |
| CA3117870A1 (fr) | 2020-06-18 |
| CN113179641B (zh) | 2024-01-02 |
| WO2020120521A1 (fr) | 2020-06-18 |
| BR112021009443A2 (pt) | 2021-08-17 |
| CR20210305A (es) | 2021-07-20 |
| JP2022513466A (ja) | 2022-02-08 |
| KR20210102900A (ko) | 2021-08-20 |
| SG11202103340PA (en) | 2021-04-29 |
| IL283823A (en) | 2021-07-29 |
| CO2021006837A2 (es) | 2021-06-10 |
| IL283823B2 (en) | 2024-07-01 |
| EP3894411A1 (fr) | 2021-10-20 |
| AU2019395774A1 (en) | 2021-04-08 |
| CN113179641A (zh) | 2021-07-27 |
| TW202039499A (zh) | 2020-11-01 |
| IL283823B1 (en) | 2024-03-01 |
| IL310081A (en) | 2024-03-01 |
| CL2021001547A1 (es) | 2021-12-24 |
| TWI831892B (zh) | 2024-02-11 |
| EP3894411B1 (fr) | 2024-06-19 |
| AR116906A1 (es) | 2021-06-23 |
| US20220056036A1 (en) | 2022-02-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA49402A (fr) | Polynucléotides aadc pour le traitement de la maladie de parkinson | |
| GEP20207149B (en) | Allosteric modulators of nicotinic acetylcholine receptors | |
| CL2016002661A1 (es) | Compuestos derivados de isoindolin-1-ona, con actividad del receptor colinérgico muscarínico m1 del modulador alostérico positivo; composición farmacológica; útiles para el tratamiento del alzheimer, esquizofrenia, dolor, trastornos del sueño, demencia asociada al parkinson o demencia con cuerpos de lewy. | |
| MA49279A (fr) | Compositions d'anticorps optimisées pour le traitement de troubles oculaires | |
| MA52747A (fr) | Composés tétrahydro-1h-pyrazino[2,1-ajisoindolylquinoline pour le traitement d'une maladie auto-immune | |
| MA39783A (fr) | Dérivés de quinoxaline utiles en tant que modulateurs de la fgfr kinase | |
| MA51558A (fr) | Dérivés de 2,4,6,7-tétrahydro-pyrazolo[4,3-d]pyrimidin-5-one et composés apparentés en tant que modulateurs du récepteur c5a pour le traitement de la vascularite et de maladies inflammatoires | |
| MA39427B1 (fr) | Composés pyrrolidine modulateurs de gpr40 pour le traitement de maladies telles que le diabète | |
| IL275781A (en) | Background 1,3,4,5-Tetrahydro-2H-pyrido[4,3-B]indole for the treatment, mitigation or prevention of disorders associated with TAU aggregates such as Alzheimer's disease | |
| MX2017011598A (es) | Metodos para tratar proteinopatias. | |
| BR112016007016A8 (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, uso de um composto, e, composição farmacêutica | |
| CO2021002670A2 (es) | Inhibidores de la interacción proteína-proteína keap1-nrf2 | |
| MA41041A (fr) | Dérivés de benzothiazole substitués utilisés en tant qu'agonistes de gpr40 pour le traitement du diabète de type ii | |
| MA55594A (fr) | Composés hexahydro-1h-pyrazino[1,2-a]pyrazine pour le traitement d'une maladie auto-immune | |
| MA54132A (fr) | Méthodes de traitement de la maladie de crohn avec un anticorps spécifique anti-il23 | |
| EA200801302A1 (ru) | Композиции и способы лечения нарушений цнс | |
| EA201691831A1 (ru) | Гетероароматические соединения и их применение в качестве допаминовых d1 лигандов | |
| PE20210052A1 (es) | Moduladores alostericos de espiropiperidina de receptores nicotinicos de acetilcolina | |
| IL291338A (en) | 1,4-dihydrobenzo[d]pyrazolo[f-3,4]diazepine derivatives and related compounds as modulators of lrrk2, nuak1 and/or tyk2 kinase for the treatment of diseases such as autoimmune diseases | |
| EA201691788A1 (ru) | Гетероароматические соединения и их применение в качестве допаминовых d1 лигандов | |
| MX2020008523A (es) | Compuesto que tiene actividad agonista del receptor esfingosina-1-fosfato [(2s,3r,4e)-2-amino-3-hidroxioctadec-4-enil- 1-fosfato (s1p5). | |
| MA54447A (fr) | Dérivés de 7-phénoxy-n-(3-azabicyclo[3.2.1]octan-8-yl)-6,7-dihydro-5h-pyrrolo[1,2-b][1,2,4]triazol-2-amine et composés apparentés en tant que modulateurs de gamma-sécrétase pour le traitement de la maladie d'alzheimer | |
| MA50495A (fr) | Composés bicycliques à fusion 5,6 et compositions pour le traitement de maladies parasitaires | |
| MA45665B1 (fr) | Dérivés d'éthynyle | |
| BR112018073396A2 (pt) | combinação de antagonistas, uso de uma combinação, método para o tratamento de desordens cognitivas, composto, método para o tratamento de doença de alzheimer e composição farmacêutica |